CNS Pharmaceuticals, Inc.
CNSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 226.95 | -5.28 | 8,768.89 |
| FCF Yield | -74.69% | -0.01% | -0.01% | -0.00% |
| EV / EBITDA | -1.13 | -12,574.76 | -10,668.17 | -61,630.81 |
| Quality | ||||
| ROIC | -229.17% | 456.64% | -174.80% | -206.66% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.15 | 0.75 | 0.69 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -21.02% | -33.91% | 22.02% | -84.63% |
| Safety | ||||
| Net Debt / EBITDA | 0.41 | 0.01 | 0.63 | 0.32 |
| Interest Coverage | -924.50 | -1,366.54 | -2,125.08 | -1,560.14 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -242,699.61 | -514,934.48 | -114,315.54 | -42,527.19 |